Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


July 28, 2014
AbbVie’s '3D' Regimen Shows Promise in Those With Hep C & HIV
AbbVie’s “3D” regimen has shown high cure rates in treating genotype 1 of hepatitis C among those coinfected with HIV, both with and without cirrhosis.
Study on Intermittent Dosing of PrEP Suggests High Adherence
Early results of a study of an intermittent dosing strategy for PrEP have suggested that a high proportion of the participants are adhering well.
July 25, 2014
Drug Spurs Latently Infected Cells But Doesn’t Taper HIV Reservoir
Romidepsin, a cancer drug from the HDAC inhibitor class, awakened HIV-infected immune cells from latency, but it did not shrink the viral reservoir.
July 24, 2014
Scientists Devise Method of Snipping HIV From Immune Cells
Researchers have created a genetic treatment that, for the first time, has succeeded in removing HIV from infected human cells.
July 23, 2014
Expert Panel’s Advice for HIV Prevention Includes PrEP
A panel of HIV experts assembled by the International Antiviral Society has issued HIV prevention and treatment guidelines for clinicians that recommend an array of evidence-based biomedical and behavioral interventions and treatments.
Young Drug Users at Especially High Risk of HIV and Hep C
Over half of young injection drug users in the United States share syringes and about four in five report having sex without a condom.
European Economic Downturn Tied to HIV Uptick in Drug Users
The recent recession in Europe and expanding income inequality have been linked to increased rates of HIV in injection drug users in the region.
Gilead Reaps $3.48 Billion in Second Quarter Sovaldi Sales
With $3.48 billion in sales of the hepatitis C drug Sovaldi, Gilead Sciences reported a second-quarter revenue of $6.53 billion.
July 22, 2014
Treating Early May Limit HIV Reservoir, But Virus Still Rebounds
Very early treatment limits the size of the viral reservoir in primates infected with an HIV-like virus, but the virus still rebounds after treatment interruption.
100% Efficacy for Gays Who Adhered in PrEP Study; Most Didn’t
Gay men and trans women mostly adhered poorly to Truvada as PrEP in a recent study, but were totally protected against HIV if they took the drug four or more days a week.
Circumcision Reduces Syphilis Rates in Both Men and Women
male circumcision reduced syphilis incidence by 42 percent in men and by 59 percent in their female partners
Sovaldi and Ribavirin Cure High Rates of Those With HIV & Hep C
Sovaldi (sofosbuvir) and ribavirin cured between 84 percent and 91 percent of people coinfected with HIV and genotypes 1 through 4 of hepatitis C.
It's Time to 'Step Up the Pace' Against Global HIV
Accelerating the response to the global HIV epidemic requires targeting key affected populations and tailoring efforts around geographic particulars, and it should involve amped up testing and treatment for the virus.
July 21, 2014
PrEP May Be Safe for Women Seeking to Get Pregnant
Truvada as pre-exposure prophylaxis may be safe for the pregnancies of HIV-negative women when taken until just after conception.
Only 1 in 5 Sexually Active High Schoolers Have Had an HIV Test
Just 22 percent of U.S. high school students who reported intercourse last year have ever received an HIV antibody test.
Egrifta Can Reduce Abdominal and Liver Fat in People With HIV
The injectable drug Egrifta (tesamorelin) led to modest drops in abdominal and liver fat levels in a preliminary study of people with HIV.
As Global Pandemic Abates, 54% of Those With HIV Are Unaware
A new UNAIDS report celebrates significant drops in global HIV incidence and AIDS-related deaths while outlining ways to address inequities of the pandemic.
July 18, 2014
Gay Men Who Discuss HIV Before Sex More Likely to Stay Negative
A new study of German gay men finds that those who discuss HIV before sex are much less likely to acquire the virus.
July 17, 2014
People With Both HIV & Hep C Have Raised Risk of Bone Loss
People coinfected with HIV and hepatitis C have a higher risk of osteoporosis and bone fracture than those who are infected with just HIV.
July 16, 2014
Sustiva (Efavirenz) Linked to Doubled Risk of Suicidality
People with HIV starting treatment regimens containing Sustiva have a more than doubled risk of suicidal thoughts, attempts and completed attempts.
July 15, 2014
Many People With HIV Could Switch to Newer, Safer Regimens
A majority of people taking antiretrovirals to treat HIV could switch to newer regimens with improved side effect profiles.
July 12, 2014
WHO Supports PrEP, Media Bungles The Story With Hyperbole
The World Health Organization has for the first time thrown its support behind the use of pre-exposure prophylaxis (PrEP to prevent HIV among gay men. 
July 11, 2014
HIV Returns in the 'Mississippi Baby' Once Thought Cured
The child has experienced a resurgence of the virus and is once again taking antiretroviral therapy.
July 10, 2014
PrEP May Reduce Risk of Herpes By a Third
Pre-exposure prophylaxis (PrEP) to prevent getting HIV may also lower the risk of contracting herpes.
July 09, 2014
WHO TasP Guidelines Will Benefit Few in the Ivory Coast
The WHO 2013 guidelines for using antiretrovirals to prevent the transmission of HIV will benefit a fraction of the targeted group in the Ivory Coast.
July 08, 2014
Intervention Boosts Minority Participation in HIV Studies
Researchers have devised an intervention that vastly increases African-American and Latino participation in HIV/AIDS medical studies.
July 07, 2014
People With HIV Less Likely to Receive Cancer Treatment
HIV-positive people are less likely to receive treatment for cancer than those who are not living with the virus.
July 03, 2014
Starting ARVs Soon After Birth Can Vastly Reduce HIV Reservoir
Treating HIV-positive infants with an aggressive regimen of HIV meds shortly after birth can greatly reduce the establishment of the viral reservoir.
July 02, 2014
Herpes Drives Heterosexual Transmission of HIV in NYC
Infection with herpes simplex virus 2 is propelling significant increases in the prevalence of HIV among non-injecting drug users in New York City.
July 01, 2014
Gay Men at Risk May Not See Themselves as PrEP Candidates
A significant proportion of gay and bi men attending New York City sex venues mistakenly qualified themselves as not being candidates for PrEP.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dave41
    Bethany
    Oklahoma


    zeze42
    Bay Area - Peninsula
    California


    usuallyhappy
    Palm Springs
    California


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.